Developing cell therapies involves navigating one of the most challenging regulatory landscapes in the life sciences. From preclinical studies to Investigational New Drug (IND) applications, manufacturing controls, and clinical trial design, the stakes are high at every phase. That’s why working with a cell therapy regulatory advisor isn’t just helpful—it’s essential.
Before hiring an expert, you need to know what to ask. The right questions will help you identify whether the advisor understands your specific product class, development phase, and regulatory jurisdiction. Specialized firms like CERES cell therapy regulatory consulting bring deep knowledge to the table, but it’s your responsibility to ensure their expertise aligns with your goals.
1. Do You Have Experience with My Type of Cell Therapy?
Cell therapies vary widely in their structure and mechanism. Some are autologous (patient-derived), others allogeneic (donor-derived), and many involve gene editing or viral vectors. Ask your advisor:
- Have you worked with T-cell therapies (e.g., CAR-T), stem cells, or iPSCs?
- Are you familiar with ATMP regulations if operating in Europe?
- Can you address the regulatory differences between gene-modified and unmodified therapies?
An advisor who has experience with your product type will provide more targeted guidance and reduce the risk of compliance gaps.
2. How Do You Help Prepare IND or CTA Submissions?
Your advisor should be able to walk you through how they contribute to regulatory submissions. Ask for specifics like:
- Do you assist with preclinical study design and data integration?
- Can you help write or review the CMC section, including comparability plans?
- Have you led FDA pre-IND or EMA scientific advice meetings?
The quality of your IND or Clinical Trial Application (CTA) can determine whether you enter clinical trials on time—or face a clinical hold.
3. What’s Your Approach to Regulatory Strategy?
A good advisor doesn’t just react—they proactively plan. Ask:
- How do you prioritize regulatory milestones?
- Do you build regulatory roadmaps that align with funding and development goals?
- Can you assist with orphan designation, RMAT, or fast track requests?
A forward-looking regulatory strategy saves time, money, and frustration later in development.
4. How Do You Stay Current with Global Regulations?
Cell therapy regulations are evolving rapidly. Ask the advisor:
- How do you monitor updates from agencies like the FDA, EMA, and Health Canada?
- Have you advised clients in multiple jurisdictions?
- Are you involved in regulatory working groups or industry consortia?
Cross-border compliance and up-to-date knowledge are critical for sponsors aiming to launch globally.
5. Can You Support CMC and GMP Readiness?
Many cell therapy programs stumble at the Chemistry, Manufacturing, and Controls (CMC) stage. You’ll want an advisor who can:
- Evaluate your current manufacturing process and recommend improvements
- Guide you through GMP facility qualification or tech transfers
- Assist with batch release strategies and stability testing
Ask if they’ve worked with internal teams, CDMOs, or consultants to align production with regulatory expectations.
6. How Do You Handle Regulatory Interactions and Communication?
Successful agency communication can make or break your program. Ask the advisor:
- Do you help prepare for pre-IND or Type B meetings?
- Can you draft briefing books, lead agency interactions, and interpret feedback?
- Have you successfully lifted clinical holds or addressed FDA information requests?
Clear, proactive communication can accelerate approval timelines and reduce risk.
Conclusion
Choosing the right cell therapy regulatory advisor requires more than checking credentials—it requires asking the right questions. From product-specific experience to communication skills and global compliance knowledge, the best advisors serve as strategic partners throughout development.
